SAN JOSE, Calif., Sept. 3, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the inventor of its ovarian cancer CAR-T technology, Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 15th Biennial Ovarian Cancer Research Symposium.

加利福尼亚州圣何塞，2024年9月3日/PRNewswire/--专注于癌症治疗和预防的生物技术公司Anixa Biosciences，Inc.（“Anixa”或“公司”）（纳斯达克：ANIX）今天宣布，其卵巢癌CAR-T技术的发明者，杜克大学医学院综合免疫生物学系免疫学教授JoseR.ConejoGarcia博士将在里夫金中心和美国癌症研究协会（AACR）第15届两年一度的卵巢癌研究研讨会上发表讲话。

Dr. Conejo-Garcia will be giving the opening keynote address on Friday, September 20, 2024..

科内乔·加西亚博士将于2024年9月20日（星期五）发表开幕式主题演讲。。

During the keynote address, Dr. Conejo-Garcia will discuss Anixa's chimeric antigen receptor-T cell (CAR-T) technology, which is an autologous cell therapy comprised of engineered T cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries.

在主题演讲中，Conejo Garcia博士将讨论Anixa的嵌合抗原受体T细胞（CAR-T）技术，这是一种自体细胞疗法，由靶向促卵泡激素受体（FSHR）的工程化T细胞组成。FSHR仅在卵巢的颗粒细胞上发现免疫相关水平。

Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor-T cell) therapy, a new type of CAR-T. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute.

由于靶标是激素（嵌合内分泌）受体，并且靶标结合结构域来源于其天然配体，因此该技术被称为CER-T（嵌合内分泌受体-T细胞）疗法，这是一种新型的CAR-T。Anixa拥有Wistar Institute对该技术的全球独家许可。

Dr. Conejo-Garcia will also discuss the ongoing Phase 1 clinical trial of this technology..

Conejo Garcia博士还将讨论该技术正在进行的第一阶段临床试验。。

'I am pleased to discuss this novel FSHR-mediated CAR-T technology at the Ovarian Cancer Research Symposium and to share ideas and advance the field of ovarian cancer research,' stated Dr. Conejo-Garcia. 'Anixa and its development partner, Moffitt Cancer Center, have been working together to advance this ovarian cancer therapy and we are excited about the clinical results to date—with the treatment appearing to be safe and well-tolerated, and some patients exhibiting tumor necrosis.

科内乔·加西亚博士说：“我很高兴在卵巢癌研究研讨会上讨论这种新型FSHR介导的CAR-T技术，并分享想法，推进卵巢癌研究领域。”Anixa及其开发合作伙伴Moffitt癌症中心一直在合作推进这种卵巢癌治疗，我们对迄今为止的临床结果感到兴奋，该治疗似乎安全且耐受性良好，并且一些患者表现出肿瘤坏死。

If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer.'.

如果这种治疗方法成功，这可能会使卵巢癌的整体治疗范式发生重大转变。”。

More information about the event may be found at: https://rivkin.org/symposia/ocrs/.

有关该活动的更多信息，请访问：https://rivkin.org/symposia/ocrs/.

About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology.

关于Anixa Biosciences，Inc.Anixa是一家临床阶段生物技术公司，专注于癌症的治疗和预防。Anixa的治疗组合包括与Moffitt癌症中心合作开发的卵巢癌免疫治疗计划，该计划使用一种新型CAR-T，称为嵌合内分泌受体-T细胞（CER-T）技术。

The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.

该公司的疫苗组合包括与克利夫兰诊所合作开发的疫苗，以预防乳腺癌，特别是三阴性乳腺癌（TNBC），这种疾病最致命的形式，以及卵巢癌，以及用于治疗许多难治性癌症的其他癌症疫苗，包括肺癌，结肠癌和前列腺癌的高发恶性肿瘤。

These vaccine technologies focus on immunizing against 'retired' proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization.

这些疫苗技术的重点是针对已发现在某些形式的癌症中表达的“退役”蛋白质进行免疫。Anixa在各个发展阶段与世界知名研究机构合作的独特商业模式使公司能够不断研究互补领域的新兴技术，以进一步开发和商业化。

To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube..

要了解更多信息，请访问www.anixa.com或在Twitter、LinkedIn、Facebook和YouTube上关注anixa。。

Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.

前瞻性陈述非历史事实的陈述可被视为1995年《私人证券诉讼改革法案》所指的前瞻性陈述。前瞻性陈述不是对历史事实的陈述，而是反映了安妮莎目前对未来事件和结果的期望。

We generally use the words 'believes,' 'expects,' 'intends,' 'plans,' 'anticipates,' 'likely,' 'will' and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

我们通常使用“相信”、“期望”、“打算”、“计划”、“预期”、“可能”、“意志”等词语来识别前瞻性陈述。此类前瞻性声明，包括与我们的预期有关的声明，涉及风险、不确定性和其他因素，其中一些因素超出了我们的控制范围，这可能导致我们的实际结果、业绩或成就或行业结果与此类前瞻性声明明示或暗示的任何未来结果、业绩或成就存在重大差异。

These risks, uncertainties and factors include, but are not limited to, those factors set forth in 'Item 1A - Risk Factors' and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

这些风险、不确定性和因素包括但不限于“第1A项-风险因素”和我们最近的10-K表年度报告其他章节以及10-Q表季度报告和8-K表当前报告中规定的因素。除法律要求外，我们没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因。

You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release..

在评估本新闻稿中提供的信息时，请注意不要过度依赖此类前瞻性声明。。

Contact:Mike CatelaniPresident, COO & CFOmcatelani@anixa.com408-708-9808

联系人：Mike Catelani总裁兼首席运营官&CFOmcatelani@anixa.com408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-therapy-at-the-rivkin-center-aacr-15th-biennial-ovarian-cancer-research-symposium-302233678.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-therapy-at-the-rivkin-center-aacr-15th-biennial-ovarian-cancer-research-symposium-302233678.html

SOURCE Anixa Biosciences, Inc.

来源Anixa Biosciences，Inc。